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Abstract
Background—Several cancer-associated loci identified from genome-wide association studies 
(GWAS) have been associated with risks of multiple cancer sites, suggesting pleiotropic effects. 
We investigated whether GWAS-identified risk variants for other common cancers are associated 
with risk of esophageal adenocarcinoma (EA) or its precursor, Barrett's esophagus (BE).
Methods—We examined the associations between risks of EA and BE and 387 single nucleotide 
polymorphisms (SNPs) that have been associated with risks of other cancers, by using genotype 
imputation data on 2,163 control participants and 3,885 (1,501 EA and 2,384 BE) case patients 
from the Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study, and investigated 
effect modification by smoking history, body mass index (BMI), and reflux/heartburn.
Results—After correcting for multiple testing, none of the tested 387 SNPs were statistically 
significantly associated with risk of EA or BE. No evidence of effect modification by smoking, 
BMI, or reflux/heartburn was observed.
Conclusions—Genetic risk variants for common cancers identified from GWAS appear not to 
be associated with risks of EA or BE.
Impact—To our knowledge, this is the first investigation of pleiotropic genetic associations with 
risks of EA and BE.
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Introduction
The incidence of esophageal adenocarcinoma (EA) has increased substantially over the past 
four decades in western countries (1). Most EA arises within Barrett's esophagus (BE), a 
metaplastic transformation of the lower esophageal lining (1). Gastroesophageal reflux 
(GERD), high body mass index (BMI), and tobacco use are well-established risk factors for 
both EA and BE, although with some variations in the magnitudes of these associations. 
These risk factors, together with low consumption of fruits and vegetables, may explain 
about 70% of the EA cases (see references in (1)). Genetic factors are thought to play an 
etiologic role based on familial clustering (1). In addition, results from the Barrett's and 
Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS) support a shared 
genetic susceptibility of EA and BE (2). In further analysis of the BEAGESS data, an 
estimated 25% of the variation in EA risk is due to common genetic variants (1). However, 
from genome-wide association studies (GWAS) to date, only 7 loci have been identified to 
be associated with risk of EA or BE (2, 3), and the effects of the individual genetic variants 
are small (2, 3). Motivated by studies investigating pleiotropic associations of GWAS-
identified variants, some of which work has identified additional risk-associated loci for 
colorectal, endometrial, and pancreatic cancers (see references in (4)), we investigated in 
BEAGESS whether cancer-GWAS-identified variants could also influence the risk of EA 
and BE.
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Details of the design and methods of BEAGESS have been described elsewhere (2). In brief, 
this ancillary study included 1,504 EA and 2,384 BE case patients and 2,163 control 
participants, all of European descent and for whom genome-wide genotyping and imputation 
was conducted and phenotype covariate data were available. We identified 407 single 
nucleotide polymorphisms (SNPs) that have previously been associated with one or more 
cancer sites at a P-value<5×10-8 in the National Human Genome Research Institute 
(NHGRI) GWAS catalog as of March 2014 (5). Genotyping was done using the Illumina 
Human Omni1-Quad platform. Imputation was performed using MaCH and Minimac 
software and a European reference panel from the 1000 Genomes project (2). This analysis 
included 387 of the 407 SNPs that had minor allele frequencies (MAF) >1% and passed 
genotyping and imputation quality control (e.g. imputation r2≥0.3) (2). We investigated 
associations with EA, BE, and for these conditions combined (EA/BE). Odds ratios (ORs) 
and 95% confidence intervals (CI) were calculated using unconditional logistic regression of 
case status on additive SNP genotype score, with adjustments for age, sex, and the first four 
principal components analysis eigenvectors (2). We performed stratum-specific analyses by 
smoking status (never, former, or current), smoking intensity (never, <30 pack-years, or ≥30 
pack-years), BMI (<25, 25-<30, or ≥30 kg/m2), and history of reflux/heartburn (yes, no), 
and tested for the statistical significance of the interaction (product) term. Some SNPs 
included in the NHGRI catalog are in linkage disequilibrium with each other. Thus, we 
calculated ‘P-values adjusted for correlated tests’ to account for multiple testing of 
correlated SNPs (6). The adjusted P values (Padj) < 0.05 are considered statistically 
significant. Analyses were conducted using SAS 9.2 (SAS Inc., NC) and R. All P values are 
two sided.
Results
After correcting for multiple testing, none of the 387 SNPs were associated with risk of EA, 
BE, or EA/BE combined (Table 1 and Supplementary Table S1). No evidence was seen for 
effect modification by smoking status or intensity, BMI, or reflux/heartburn history (data not 
shown).
Discussion
Studies investigating pleiotropic effects of GWAS-identified risk variants have revealed 
additional risk loci for endometrial, colorectal, and pancreatic cancer, but not for estrogen-
receptor (ER)-negative breast cancer (ER-positive cancers were not investigated), prostate 
cancer, or non-Hodgkin lymphoma (4, 7-9). Some studies, including those of non-Hodgkin 
lymphoma, endometrial cancer, and colorectal cancer, investigated cancer GWAS hits while 
studies of pancreatic cancer, prostate cancer, and ER-negative breast cancer investigated 
cancer and non-cancer GWAS-hits (4, 7-9). Our investigation based on cancer GWAS SNPs 
is not supportive of shared genetic susceptibility between EA/BE and other cancer sites. To 
our knowledge, this is the first study to investigate pleiotropic associations of cancer GWAS 
loci on risks of EA and BE. Although our study sample size is moderate, the combined 
number of EA and BE cases is larger than that of most previous studies on cancer pleiotropy 
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(4, 7-9). For SNPs with MAF of 0.3 (the average MAF of all tested SNPs), we had 80% 
statistical power to detect an OR of 1.21 per minor allele for analyses on EA/BE combined, 
with a Bonferroni-corrected type I error rate of 5%. Given that nearly one-half (47%) of the 
NHGRI-catalogued cancer-GWAS SNPs were from studies of more common cancers 
(Supplementary Table S1), it may be fruitful to repeat this analysis when additional GWAS 
loci identified from less common cancers become available.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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